ArticleAlimentary pharmacology & therapeutics2026
High Risk of Colorectal Cancer After High-Grade Dysplasia in Inflammatory Bowel Disease Patients.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are limited data on colorectal cancer (CRC) risk after high-grade dysplasia in inflammatory bowel disease.
aimsTo determine the long-term CRC and neoplasia risk after a first diagnosis of high-grade dysplasia in inflammatory bowel disease, and to assess utilisation of high-grade dysplasia treatment strategies over the past three decades.
methodsIn this nationwide retrospective cohort study, patients with colonic inflammatory bowel disease and high-grade dysplasia diagnosis between 1991 and 2021 were extracted from the Dutch nationwide pathology databank (PALGA). The primary outcome was the cumulative incidence of metachronous CRC. Kaplan-Meier curves were used to show proctocolectomy-free survival per decade.
resultsCRC was diagnosed in 348 of 1220 patients (28.5%). Of these, 204 (16.7%) were diagnosed with CRC within 6 months after the first high-grade dysplasia diagnosis and were considered synchronous patients. Metachronous CRC was diagnosed in 144 of 1016 patients (14.2%) after a median of 3.6 years. The 1-, 5- and 10-year cumulative incidences of metachronous CRC after high-grade dysplasia were 2.9%, 9.9% and 15.5%, respectively. The 1-, 5- and 10-year cumulative incidences of metachronous neoplasia were 18.3%, 51.2% and 68.0%, respectively. Proctocolectomy-free survival after high-grade dysplasia decreased over time.
conclusionsThe risk of synchronous and metachronous CRC after a diagnosis of high-grade dysplasia underlines the high-risk profile of this subgroup of patients with inflammatory bowel disease. The possible advantages of colon-sparing treatment should be balanced with the higher risk of metachronous CRC and the subsequent need for stringent endoscopic surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.